Product: TRAF6 Antibody
Catalog: AF5376
Source: Rabbit
Application: WB, IHC, IF/ICC, ELISA(peptide)
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 58 kD; 60kD(Calculated).
Uniprot: Q9Y4K3
RRID: AB_2810280

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(90%), Sheep(90%), Rabbit(100%), Dog(100%), Chicken(90%)
Clonality:
Polyclonal
Specificity:
TRAF6 Antibody detects endogenous levels of total TRAF6.
RRID:
AB_2810280
Cite Format: Affinity Biosciences Cat# AF5376, RRID:AB_2810280.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

E3 ubiquitin-protein ligase TRAF6; Interleukin 1 signal transducer; Interleukin-1 signal transducer; MGC 3310; MGC:3310; MGC3310; OTTHUMP00000232772; OTTHUMP00000232773; RING finger protein 85; RNF 85; RNF85; TNF receptor associated factor 6; TNF receptor-associated factor 6; TNF receptor-associated factor 6, E3 ubiquitin protein ligase; TRAF 6; Traf6; TRAF6_HUMAN;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
Q9Y4K3 TRAF6_HUMAN:

Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Description:
Tumor necrosis factor receptor-associated factor 6 (TRAF6) regulates adaptive immunity, innate immunity and bone metabolism. TRAF6 is a ubiquitin (Ub) ligase that mediates the activation of protein kinases, such as transforming growth factor beta-activated kinase (TAK1) and IκB kinase (IKK)
Sequence:
MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Dog
100
Rabbit
100
Bovine
90
Sheep
90
Chicken
90
Zebrafish
78
Horse
0
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9Y4K3 As Substrate

Site PTM Type Enzyme
K104 Ubiquitination
K124 Ubiquitination
S188 Phosphorylation
Y326 Phosphorylation
K331 Ubiquitination
K365 Ubiquitination
T486 Phosphorylation
K489 Ubiquitination
T492 Phosphorylation
S507 Phosphorylation

Research Backgrounds

Function:

E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2. Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. May be essential for the formation of functional osteoclasts. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production.

PTMs:

Sumoylated on Lys-124, Lys-142 and Lys-453 with SUMO1.

Polyubiquitinated on Lys-124; after cell stimulation with IL-1-beta or TGF-beta. This ligand-induced cell stimulation leads to dimerization/oligomerization of TRAF6 molecules, followed by auto-ubiquitination which involves UBE2N and UBE2V1 and leads to TRAF6 activation. This 'Lys-63' site-specific poly-ubiquitination appears to be associated with the activation of signaling molecules. Endogenous autoubiquitination occurs only for the cytoplasmic form. Deubiquitinated by USP10 in a TANK-dependent manner, leading to the negative regulation of NF-kappaB signaling upon DNA damage.

Subcellular Location:

Cytoplasm. Cytoplasm>Cell cortex. Nucleus. Lipid droplet.
Note: Found in the nuclei of some aggressive B-cell lymphoma cell lines as well as in the nuclei of both resting and activated T- and B-lymphocytes. Found in punctate nuclear body protein complexes. Ubiquitination may occur in the cytoplasm and sumoylation in the nucleus. RSAD2/viperin recruits it to the lipid droplet (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Subunit Structure:

Homotrimer. Homooligomer. N-terminal region is dimeric while C-terminal region is trimeric; maybe providing a mode of oligomerization. Upon IL1B treatment, forms a complex with PELI1, IRAK1, IRAK4 and MYD88; this complex recruits MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation. Direct binding of SMAD6 to PELI1 prevents the complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression. Binds to TNFRSF5/CD40 and TNFRSF11A/RANK. Associates with NGFR, TNFRSF17, IRAK2, IRAK3, RIPK2, MAP3K1, MAP3K5, MAP3K14, CSK, TRAF, TRAF-interacting protein TRIP and TNF receptor associated protein TDP2. Interacts with IL17R. Interacts with SQSTM1 bridging NTRK1 and NGFR. Forms a ternary complex with SQSTM1 and PRKCZ (By similarity). Interacts with PELI2 and PELI3. Binds UBE2V1. Interacts with TAX1BP1. Interacts with ZNF675. Interacts with ARRB1 and ARRB2. Interacts with MAP3K7 and TAB1/MAP3K7IP1; during IL-1 signaling. Interacts with UBE2N. Interacts with TGFBR1, HDAC1 and RANGAP1. Interacts with AKT1, AKT2 and AKT3. Interacts (via TRAF domains) with NUMBL (via C-terminal). Interacts with RBCK1. Interacts with TRAF3IP2. Interacts with LIMD1 (via LIM domains) (By similarity). Interacts with RSAD2/viperin (By similarity). Interacts (via C-terminus) with EIF2AK2/PKR (via the kinase catalytic domain) (By similarity). Interacts with ZFAND5. Interacts with IL1RL1. Interacts with TRAFD1. Interacts with AJUBA. Interacts with MAVS/IPS1. Interacts (via TRAF domains) with WDR34 (via WD domains). Interacts with IFIT3 (via N-terminus). Interacts with TICAM2. Interacts with CARD14. Interacts with CD40 and MAP3K8; the interaction is required for ERK activation (By similarity). Interacts with TICAM1 and this interaction is enhanced in the presence of WDFY1. Interacts with TANK; this interaction increases in response to DNA damage. Interacts with USP10; this interaction increases in response to DNA damage. Interacts with ZC3H12A; this interaction increases in response to DNA damage and is stimulated by TANK. Interacts with WDFY3 (By similarity). Interacts with TRIM13. Interacts with GPS2 (By similarity). Interacts (via C-terminus) with SASH1.

Family&Domains:

The coiled coil domain mediates homo- and hetero-oligomerization.

The MATH/TRAF domain binds to receptor cytoplasmic domains.

Belongs to the TNF receptor-associated factor family. A subfamily.

Research Fields

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

References

1). Wu H et al. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. Redox Biol 2020 Mar 11;32:101500 (PubMed: 32193146) [IF=9.986]

Application: WB    Species: Mice    Sample: RAW264.7 cells

Fig. 5. NK diminished LPS-induced TLR4 activation likely due to promoting TRL4 proteolysis in RAW264.7 cells. (A) Effect of NK on LPS-induced TLR4 signaling pathways. Cells were pretreated with indicated concentrations of NK for 1 h and then exposed to LPS (0.1 μg/mL) for 12 h. Equal amounts of total cell lysates were loaded and subjected to immunoblot analysis. Data represent the mean ± SD from three independent experiments. (B) NK induced TRL4 degradation via its serine protease activity in RAW264.7 cells. Cells were treated with NK (0.3 FU/mL) for indicated time points with or without PMSF pretreatment for 30 min. Equal amounts of total cell lysates were loaded and subjected to immunoblot analysis. Data represent mean ± SD from three independent experiments. *P < 0.05, **P < 0.01 compared to control group; #P < 0.05, ##P < 0.05 compared to NK 12h group; $ P < 0.05, $$P < 0.05 compared to NK 24h group.

2). Li Y et al. Interleukin 17A deficiency alleviates fluoride-induced testicular injury by inhibiting the immune response and apoptosis. Chemosphere 2021 Jan;263:128178. (PubMed: 33297146) [IF=5.778]

3). Duan Z et al. TMT-based quantitative proteomics analysis reveals the attenuated replication mechanism of Newcastle disease virus caused by nuclear localization signal mutation in viral matrix protein. Virulence 2020 Dec;11(1):607-635. (PubMed: 32420802) [IF=5.542]

Application: WB    Species: Mouse    Sample: BSR-T7/5 cells

Figure 9. rSS1GFP replication is enhanced by inhibiting TIFA/TRAF6/NF-κB signaling pathway later in infection. (A) The mRNA expression levels of TIFA gene in BSR-T7/5 cells infected with rSS1GFP and rSS1GFP-M/NLSm were verified by qRT-PCR. (B) The protein expression levels of TIFA in BSR-T7/5 cells infected with rSS1GFP and rSS1GFP-M/NLSm were examined by Western blotting. The relative expression levels of TIFA were compared with the control GAPDH expression. (C) The subcellular localization of EGFP-M or EGFP-M/NLSm and HA-TIFA in plasmids co-transfected BSR-T7/5 cells. Original magnification was 1 × 200. (D) The effect of different dosage EGFP-M or EGFP-M/NLSm on the expression level of endogenous TIFA in plasmid transfected BSR-T7/5 cells. The relative expression levels of TIFA were compared with the control GAPDH expression. (E) The expression patterns of TIFA, pTIFA, TRAF6, NF-κB p65, pNF-κB p65, and IL-2 in BSR-T7/5 cells infected with rSS1GFP and rSS1GFP-M/NLSm at 12 and 24 hpi. The relative expression levels of these proteins were compared with the control GAPDH expression. (F) The effect of TIFA overexpression on the expression of IL-2 and virus titers of rSS1GFP and rSS1GFP-M/NLSm at 12 and 24 hpi. (G) The effect of siRNA-mediated knockdown of TIFA on the expression of IL-2 and virus titers of rSS1GFP and rSS1GFP-M/NLSm at 12 and 24 hpi. (H) The schematic diagram illustrated that the M protein in the cytoplasm inhibited host cell immune response by down-regulating TIFA/TRAF6/NF-κB signaling pathway

4). Hassan HM et al. Adamantane-linked isothiourea derivatives suppress the growth of experimental hepatocellular carcinoma via inhibition of TLR4-MyD88-NF-κB signaling. Am J Cancer Res 2021 Feb 1;11(2):350-369. (PubMed: 33575076) [IF=5.177]

Application: IHC    Species: rat    Sample: hepatic tissues

Figure 10.| Effect of compounds 5 and 6 on hepatic on hepatic TRAF-6 protein expression in TAA-administered rats. Representative microimages of immunostaining for TRAF-6 protein (IHC counterstained with Mayer’s hematoxylin) in hepatic tissues and statistical analysis of positive area of immunolabelling (%) are shown. Black arrows denote positive immunoexpression. Images were captured at magnification of 100× (scale bar, 100 µm) or 400× (scale bar, 50 µm). *P < 0.05 vs. control group, #P < 0.05 vs. HCC group. DOXO: doxorubicin, HCC: hepatocellular carcinoma, IHC: immunohistochemistry, TAA: thioacetamide, TRAF-6: tumor necrosis factor receptor-associated factor-6.

5). Guangwei Z et al. TRAF6 regulates the signaling pathway influencing colorectal cancer function through ubiquitination mechanisms. Cancer Sci 2022 Apr;113(4):1393-1405. (PubMed: 35179811) [IF=4.966]

6). Li LJ et al. Corilagin Interferes With Toll-Like Receptor 3-Mediated Immune Response in Herpes Simplex Encephalitis. Front Mol Neurosci 2019 Apr 26;12:83 (PubMed: 31080403) [IF=4.057]

Application: WB    Species: mouse    Sample: brain

Figure 10.| The expression of TLR3 and its downstream molecules in brain tissues of mice with encephalitis. DMEM (20μL), PBS (20μL), poly(I:C) (5mg/kg, 20μL), and HSV-1 (10-4/20μL) were injected into the intracalvarium at the midpoint of the line from the right canthus to external auditory canal. After the model was established for 1 h, 5 mice in each group were intragastrically treated with normal saline (NS),Corilagin 40 mg/kg, ACV 350mg/kg each day. (A) The mRNA levels of TLR3 and its downstream molecules in brain tissues were detected by RT-PCR. (B) The protein levels of TLR3 and its downstream molecules in brain tissues were measured by western blotting.

7). Li LJ et al. Corilagin Interferes With Toll-Like Receptor 3-Mediated Immune Response in Herpes Simplex Encephalitis. Front Mol Neurosci 2019 Apr 26;12:83 (PubMed: 31080403) [IF=4.057]

8). L Zhao et al. Effect of corilagin interfering with TLR3-mediated immune response in herpes simplex virus encephalitis. Front. Mol. Neurosci. 2019 Apr 26; [IF=4.057]

9). Zhu G et al. TRAF6 promotes the progression and growth of colorectal cancer through nuclear shuttle regulation NF-kB/c-jun signaling pathway. Life Sci 2019 Sep 2:116831 (PubMed: 31487530) [IF=3.647]

10). Zhu G et al. TRAF6-Mediated Inflammatory Cytokines Secretion in LPS-induced Colorectal Cancer Cells Is Regulated by miR-140. Cancer Genomics Proteomics 2020 Jan-Feb;17(1):23-33 (PubMed: 31882548) [IF=3.280]

Application: WB    Species: Human    Sample: SW480 and HCT116 cells

Figure 6 Effect of TRAF6 overexpression on miR-140-mediated inflammatory cytokine expression in LPS treated (1 μg) SW480 and HCT116 cells. (A) qPCR analysis of TRAF6 mRNA levels in SW480 cells after transfection with mimic NC, miR-140 mimic, inhibitor NC or miR-140 inhibitor. (B) Western-blot analysis of TRAF6 protein levels in SW480 cells after transfection with mimic NC, miR-140 mimic, inhibitor NC or miR-140 inhibitor. (C) qPCR analysis of TRAF6 mRNA levels in SW480 cells after transfection with pcDNA3.1 or pcDNA3.1-TRAF6. (D) Western blot analysis of TRAF6 protein levels in SW480 cells after transfection with pcDNA3.1 or pcDNA3.1-TRAF6. (E) ELISA analysis of TNF-α, IL-6, COX-2, MMP-7 and VEGF-C protein levels in LPS-treated (1 μg) SW480 cells with transfection of mimic NC+pcDNA3.1, miR-140 mimic+pcDNA3.1,mimic NC+pcDNA3.1-TRAF6 or miR-140 mimic+pcDNA3.1-TRAF6. (F) ELISA analysis of TNF-α, IL-6, COX-2, MMP-7 and VEGF-C protein levels in LPS treated (1 μg) HCT116 cells after transfection of mimic NC+pcDNA3.1, miR-140 mimic+pcDNA3.1, mimic NC+pcDNA3.1-TRAF6 or miR-140 mimic+pcDNA3.1-TRAF6. (G) qPCR analysis of TRAF6 mRNA levels in HCT116 cells after being transfected with mimic NC, miR- 140 mimic, inhibitor NC or miR-140 inhibitor. (H) Western-blot analysis of TRAF6 protein levels in HCT116 cells after being transfected with mimic NC, miR-140 mimic, inhibitor NC or miR-140 inhibitor. (I) qPCR analysis of TRAF6 mRNA levels in HCT480 cells after being transfected with pcDNA3.1 or pcDNA3.1-TRAF6. (J) Western blot analysis of TRAF6 protein levels in HCT116 cells after being transfected with pcDNA3.1 or pcDNA3.1-TRAF6. *p<0.05, **p<0.01 and ***p<0.001.

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.